SECOND QUARTER 2012
Mr. Pierre Laurin reports
PROMETIC REPORTS ITS SECOND QUARTER 2012 HIGHLIGHTS AND FINANCIAL RESULTS
ProMetic Life Sciences Inc. had revenue of $6.3-million and net profit of $800,000 for the second quarter of 2012 (quarter ended June 30, 2012).
Revenue of $6.3 million in the second quarter was driven by strong product sales in ProMetic's bioseparation business as well as by licensing revenues from two strategic plasma-derived therapeutic deals.
"We are pleased to see that our continued efforts to establish short term financial self-sufficiency and long term sustainability are proving successful. We have seen the strengthening of our base case business for 2012 with over $16 million of purchase orders and contracts secured in the second quarter alone and we anticipate ongoing strong results in the second half of 2012", stated Mr. Pierre Laurin, ProMetic's President and Chief Executive Officer.''
https://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aPLI-1985277&symbol=PLI®ion=C